Welcome to our dedicated page for ASTROTECH SEC filings (Ticker: ASTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Astrotech Corporation filings document an instrumentation company organized around subsidiaries applying mass spectrometry and gas chromatography to security screening, narcotics detection, agriculture processing, industrial process control, breath analysis, and environmental testing. Results-related 8-K reports include operating updates for product lines such as TRACER 1000 and EN-SCAN.
The filing record also covers security-holder rights under the company's rights agreement, annual meeting voting matters, executive compensation and governance disclosures in proxy materials, officer changes, consulting arrangements, and transaction-related compensation plans. These disclosures describe ASTC's capital structure, board oversight, compensation framework, and material-event reporting obligations.
Nihanth Badugu, Chief Operating Officer of Astrotech Corporation (ASTC), filed an initial Form 3 reporting ownership of employee stock options. The filing lists two option grants: an option covering 1,800 common shares with an $11.87 exercise price (expiration shown 08/07/2033) and an option covering 840 common shares with an $11.51 exercise price (expiration shown 08/28/2034). The first grant vests in three equal annual installments beginning on the first anniversary of the grant (600 shares vested on 08/07/2024 and 600 shares vested on 08/07/2025). The second grant also vests in three equal annual installments (280 shares vested on 08/28/2025). The Form is signed and dated 08/28/2025.
Astrotech Corporation announced the appointment of Nihanth Badugu as Chief Operating Officer, effective August 13, 2025. Mr. Badugu, age 37, has served as the company’s Director of Program Management since August 2023 and previously held program and NPI management roles at Thermo Fisher Scientific and PVA Consulting Group. The Compensation Committee set his annual base salary at $225,000 and awarded 5,000 stock options with a strike price equal to the closing price on August 13, 2025; vesting will follow a schedule determined by the Committee tied to performance and retention. He is eligible for an annual performance bonus equal to 25% of base salary ($56,250), which is doubled if gross margin targets are met, with potential additional bonuses for outperformance. The filing states there are no related-party transactions or family relationships requiring disclosure.